RxConsultant.com

Save time, stay current, and earn CE. You can rely on The Rx Consultant to deliver practical easy-reading updates on drugs & therapy for front-line pharmacists and nurses.

CE for this article is no longer valid.
Non Subscriber: Buy This Issue

Evaluating the Risks of Second Generation Antipsychotic Use in Elders with Dementia

Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for the issue, return to this Introduction page and click the "Take the Test" button. The Introduction page will remain open after you open this issue. You may need to re-size or close the issue in order to see the Introduction page.

Overview

   Dementia develops in 5-8% of adults over the age of 65 years and 25-50% of those over 85 years of age. In addition to a progressive decline in cognition and functioning, patients commonly exhibit behavioral and psychological symptoms of dementia (BPSD). These include physical or verbal aggression, wandering, restlessness, anxiety, depression, sleep disturbance, and psychotic symptoms such as hallucinations and delusions. BPSD contributes substantially to patient distress and caregiver burden, and can result in institutionalization of the patient. Up to 90% of demented patients in nursing homes exhibit BPSD.

   Strategies to address BPSD include non-drug management, antipsychotics, cholinesterase inhibitors, antidepressants, antiepileptics, and benzodiazepines. Among these options, second generation antipsychotics (SGAs) are widely used, although none have been FDA approved for this indication and there are serious safety concerns linked with their use. This issue summarizes the limited efficacy and tolerability of SGAs when they are used in demented older adults. Detailed explanations of the increased risk for stroke, death, tardive dyskinesia and pneumonia that are associated with SGAs are provided. Ways to minimize adverse effects are discussed along with a comprehensive list of recommendations for non-drug approaches to assist patients with BPSD. Improving quality of care in this vulnerable population requires that healthcare providers be fully cognizant of the risks and benefits of treatment and that patients’ caregivers are making fully informed decisions about using these medications.

Details

Publication Date: 05/01/2009
Expiration Date: 05/31/2012
CE Credit: 1.5 (0.15 CEU)
Type of Activity: Knowledge-based

This program was developed by The Rx Consultant and published by Continuing Education Network, Inc. The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased, balanced information to health care practitioners.

Programs developed by The Rx Consultant are written by health care providers with expertise in the topic area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure that every program presents information that is current, accurate, relevant to "real world" health care providers, and written in an easy reading, "plain English" style.

Authors

Tami L. Remington, Pharm.D., Clinical Associate Professor, College of Pharmacy, University of Michigan; and Clinical Pharmacist, UM Turner Geriatric Clinic, Ann Arbor, MI. Trisha D. Wells, Pharm.D., Clinical Assistant Professor, College of Pharmacy, University of Michigan and Clinical Pharmacist, UM Health System, Ann Arbor, MI.

Disclosure Statement

Remington and Dr. Wells report no financial or personal relationship with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.

Target Audience

This accredited program is targeted to pharmacists and nurses.

Goals & Objectives

At the conclusion of this program, participants will be able to:

    1. Describe the impact of BPSD on patients and caregivers
    2. Characterize the potential benefits of antipsychotic medications in treating BPSD.
    3. Identify major risks of antipsychotic medications in demented older adults, citing actual rates of these events observed in clinical trials or observational studies.
    4. Assist patients and families to ensure the decision to initiate treatment is an informed one.
    5. Work with patients, families and other health care providers to monitor for and minimize the risk for serious adverse events linked with antipsychotic use.

Accreditation Statements

The Rx Consultant is a publication of Continuing Education Network, Inc. Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education as a provider of continuing pharmacy education.

Continuing Education Network is approved by the California Board of Registered Nursing, Provider Number CEP 13118. Programs approved by CA BRN are accepted by most State Boards of Nursing.

Exam & Credit Statement Procedures

Upon successful completion of this program and the post test (70%), 1.5 hours of continuing education credit will be awarded. To receive credit and your exam score, please complete the exam questions and program evaluation.

Editorial and Review Board

Editor and CE Administrator

Terry M. Baker, PharmD

Associate Editor and CE Coordinator

Tracy Farnen, PharmD

Associate Editors

James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Kaiser Permanente
Oakland, CA

Associate Clinical Professor
School of Pharmacy
University of California San Francisco
San Francisco, CA

Ron Finley, RPh
Lecturer
Department of Clinical Pharmacy
University of California San Francisco
San Francisco, CA

Associate Member of the UCSF Memory and Aging Center
Alzheimer's Research Center

Consultant Pharmacist to the Institute on Aging-On Lok Senior Health
Institute on Aging Alzheimer's Day Care Center

Angie S. Graham, PharmD
Drug Information Coordinator
Stanford Hospital and Clinics
Stanford University Medical Center
Stanford, CA

Julio R. Lopez, PharmD, FCSHP
Chief of Pharmacy Service
VA Northern California Health Care System

Adjunct Clinical Professor
College of Pharmacy
Touro University
Vallejo, CA

Assistant Clinical Professor
School of Pharmacy
University of California, San Francisco
San Francisco, CA

Adjunct Professor
Thomas J. Long School of Pharmacy
University of the Pacific
Stockton, CA

Visiting Associate Professor and Lecturer
Nursing School
Samuel Merritt University
Oakland, CA

Pamela Mausner, MD

Joshua J. Neumiller, PharmD, CDE, CGP, FASCP
Assistant Professor
Department of Pharmacotherapy
College of Pharmacy
Washington State University
And
Elder Services of Spokane
Spokane, WA

Candy Tsourounis, PharmD
Professor of Clinical Pharmacy
Medication Outcomes Center
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
San Francisco, CA

Senior Editorial Advisor

Gerard Hatheway, PharmD, PhD

Editorial Advisors

Jocelyn Chan, PharmD
Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD


Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners

Emily K. Meuleman, RN, C, MS

About the Rx Consultant

The Rx Consultant is a monthly publication dedicated to providing health care professionals with the information they need to educate patients about drugs and manage drug therapy. The reader is responsible for confirming the information presented here and interpreting it in relation to each patient's specific situation before utilizing the information.

Contact Us

Exam Processing Inquiries

The Rx Consultant
mail@rxconsultant.com
1-800-798-3353

Educational Content Inquiries

The Rx Consultant
editor@rxconsultant.com
1-800-798-3353

CE for this article is no longer valid.
Non Subscriber: Buy This Issue